NRG-103
/ Nurenje Biomedical Technology
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
January 21, 2025
Clinical study on the safety and efficacy of NRG-103 injection in the treatment of recurrent glioblastoma patients
(ChiCTR)
- P=N/A | N=15 | Recruiting | Sponsor: Zhongnan Hospital of Wuhan University; Zhongnan Hospital of Wuhan University
New trial • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor
January 04, 2025
Safety and Efficacy of NRG-103 Injection in the Treatment of Recurrent Glioblastoma Patients
(clinicaltrials.gov)
- P1 | N=15 | Recruiting | Sponsor: Zhongnan Hospital
New P1 trial • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor
1 to 2
Of
2
Go to page
1